KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CRISPR Therapeutics AG (CRSP) Enterprise Value: 2015-2025

Historic Enterprise Value for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Sep 2025 value amounting to $4.0 billion.

  • CRISPR Therapeutics AG's Enterprise Value rose 92.63% to $4.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 billion, marking a year-over-year increase of 59.83%. This contributed to the annual value of $1.5 billion for FY2024, which is 55.60% down from last year.
  • According to the latest figures from Q3 2025, CRISPR Therapeutics AG's Enterprise Value is $4.0 billion, which was up 60.47% from $2.5 billion recorded in Q2 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Enterprise Value registered a high of $9.7 billion during Q2 2021, and its lowest value of $1.1 billion during Q1 2025.
  • In the last 3 years, CRISPR Therapeutics AG's Enterprise Value had a median value of $2.5 billion in 2025 and averaged $2.4 billion.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Enterprise Value surged by 389.37% in 2021 and then tumbled by 72.70% in 2022.
  • Quarterly analysis of 5 years shows CRISPR Therapeutics AG's Enterprise Value stood at $3.4 billion in 2021, then crashed by 60.02% to $1.4 billion in 2022, then spiked by 139.79% to $3.3 billion in 2023, then plummeted by 55.60% to $1.5 billion in 2024, then spiked by 92.63% to $4.0 billion in 2025.
  • Its last three reported values are $4.0 billion in Q3 2025, $2.5 billion for Q2 2025, and $1.1 billion during Q1 2025.